Latest Content

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

Paricalcitol shows more consistent parathyroid hormone control and a stronger survival signal than calcitriol in chronic kidney disease, though evidence for hard outcomes remains limited.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An FDA committee voted 9-3 that available data did not provide substantial evidence of effectiveness for deramiocel in DMD.

MASLD/MASH was associated with higher mild cognitive impairment risk and lower dementia odds, but competing risks may explain the latter finding.

DLBCL and MCL patients spotlight fatigue, pain, and emotional burden while backing PRO surveys to shape quality-of-life trial endpoints.

Researchers say the Trump administration has quietly shut down most Agency for Healthcare Research and Quality grantmaking, halting 100+ safety studies.

In the DELTA TEEN trial, 64% of adolescents achieved clear or almost clear skin with delgocitinib cream vs 29% on vehicle, with mostly mild adverse events.